{"id":"fffa2127-5d46-4965-b510-cf96161154f0","name":"HistoSonics","slug":"histosonics","description":"Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.","status":null,"founded":2009,"hq":"Plymouth, MN, USA","fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://histosonics.com/","title":"HistoSonics | Leader in Histotripsy","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-edison-histotripsy-fda-kidney-tumors/","title":"HistoSonics submits Edison histotripsy tech to FDA for kidney tumors","sourceName":"MassDevice"},{"url":"https://histosonics.com/histosonics-secures-102m-series-d-financing/","title":"HistoSonics Secures $102M Series D Financing","sourceName":"HistoSonics"},{"url":"https://www.massdevice.com/histosonics-stake-acquired-2b-investor-syndicate/","title":"HistoSonics stake acquired by $2B investor syndicate","sourceName":"MassDevice"}],"keyFacts":[{"label":"Funding","value":"$102M Series D + $2B+ acquisition"},{"label":"CEO","value":"Mike Blue"},{"label":"Form factor","value":"Surgical (histotripsy / focused ultrasound)"},{"label":"FDA status","value":"De Novo authorized 2023 (liver); kidney pending"},{"label":"CE Mark","value":"July 2026"},{"label":"Founded","value":"2009"},{"label":"Stage","value":"Commercial (FDA-cleared)"},{"label":"Product","value":"Edison Histotripsy System (FDA De Novo cleared Oct 2023)"},{"label":"Total funding","value":"$102M+ Series D (Alpha Wave Ventures led)"},{"label":"Valuation","value":"$3.75B (2026)"},{"label":"FDA pathway","value":"De Novo clearance for liver tumor destruction"},{"label":"Investors","value":"Alpha Wave Ventures, Amzak Health, HealthQuest Capital, J&J Innovation"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-07-23T13:40:08.115Z","updatedAt":"2026-07-23T13:51:43.545Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/histosonics","url":"https://registry.deploy.report/companies/histosonics","name":"HistoSonics","description":"Plymouth, Minnesota-based medical device company developing the Edison Histotripsy System — a robotically assisted platform using focused ultrasound to non-invasively destroy liver tumors. FDA De Novo clearance October 2023. Raised $102M Series D led by Alpha Wave Ventures, valued at $3.75B. Expanding to kidney, pancreas, prostate applications.","identifier":"fffa2127-5d46-4965-b510-cf96161154f0","foundingDate":"2009","address":"Plymouth, MN, USA","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":4,"primary_source_types":[]}}}